Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy

被引:57
作者
Montagna, Giacomo [1 ]
Mamtani, Anita [1 ]
Knezevic, Andrea [2 ]
Brogi, Edi [3 ]
Barrio, Andrea, V [1 ]
Morrow, Monica [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Biostat Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
关键词
PATHOLOGICAL COMPLETE RESPONSE; BREAST-CANCER PATIENTS; LYMPH-NODES; FOLLOW-UP; BIOPSY; SURGERY; MULTICENTER; METASTASES; THERAPY; TRASTUZUMAB;
D O I
10.1245/s10434-020-08650-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Axillary lymph node dissection (ALND) can be avoided in node-positive patients who receive neoadjuvant chemotherapy (NAC) if three or more negative sentinel lymph nodes (SLNs) are retrieved. We evaluate how often node-positive patients avoid ALND with NAC, and identify predictors of identification of three or more SLNs and of nodal pathological complete response (pCR). Methods From November 2013 to July 2019, all patients with cT1-3, biopsy-proven N1 tumors who converted to cN0 after NAC received SLN biopsy (SLNB) with dual mapping and were identified from a prospectively maintained database. Results 630 consecutive N1 patients were eligible for axillary downstaging with NAC; 573 (91%) converted to cN0 and had SLNB, and 531 patients (93%) had three or more SLNs identified. Lymphovascular invasion (LVI; odds ratio [OR] 0.46, 95% confidence interval [CI] 0.24-0.87; p = 0.02) and increasing body mass index (BMI; OR 0.77, 95% CI 0.62-0.96 per 5-unit increase; p = 0.02) were significantly associated with failure to identify three or more SLNs. 255/573 (46%) patients achieved nodal pCR; 237 (41%) had adequate mapping. Factors associated with ALND avoidance included high grade (OR 2.51, 95% CI 1.6-3.94, p = 0.001) and receptor status (HR+/HER2- [referent]: OR 1.99, 95% CI 1.15-3.46 [p = 0.01] for HR-/HER2-, OR 3.93, 95% CI 2.40-6.44 [p < 0.001] for HR+/HER2+, and OR 8.24, 95% CI 4.16-16.3 [p < 0.001] for HR-/HER2+). LVI was associated with a lower likelihood of avoiding ALND (OR 0.28, 95% CI 0.18-0.43; p < 0.001). Conclusions ALND was avoided in 41% of cN1 patients after NAC. Increased BMI and LVI were associated with lower retrieval rates of three or more SLNs. ALND avoidance rates varied with receptor status, grade, and LVI. These factors help select patients most likely to avoid ALND.
引用
收藏
页码:4515 / 4522
页数:8
相关论文
共 39 条
[1]   Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings [J].
Alvarado-Cabrero, Isabel ;
Alderete-Vazquez, Georgia ;
Quintal-Ramirez, Marissa ;
Patino, Marcia ;
Ruiz, Erika .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2009, 13 (03) :151-157
[2]   Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed? [J].
Baker, Jennifer L. ;
Muhsen, Shirin ;
Zabor, Emily C. ;
Stempel, Michelle ;
Gemignani, Mary L. .
ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) :336-342
[3]   Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study [J].
Boileau, Jean-Francois ;
Poirier, Brigitte ;
Basik, Mark ;
Holloway, Claire M. B. ;
Gaboury, Louis ;
Sideris, Lucas ;
Meterissian, Sarkis ;
Arnaout, Angel ;
Brackstone, Muriel ;
McCready, David R. ;
Karp, Stephen E. ;
Trop, Isabelle ;
Lisbona, Andre ;
Wright, Frances C. ;
Younan, Rami J. ;
Provencher, Louise ;
Patocskai, Erica ;
Omeroglu, Atilla ;
Robidoux, Andre .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :258-U150
[4]   Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) [J].
Boughey, Judy C. ;
Ballman, Karla V. ;
Le-Petross, Huong T. ;
McCall, Linda M. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Feliberti, Eric C. ;
Hunt, Kelly K. .
ANNALS OF SURGERY, 2016, 263 (04) :802-807
[5]   Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial [J].
Boughey, Judy C. ;
McCall, Linda M. ;
Ballman, Karla V. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Flippo-Morton, Teresa ;
Hunt, Kelly K. .
ANNALS OF SURGERY, 2014, 260 (04) :608-616
[6]   Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial [J].
Boughey, Judy C. ;
Suman, Vera J. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Kuerer, Henry M. ;
Bowling, Monet ;
Flippo-Morton, Teresa S. ;
Byrd, David R. ;
Ollila, David W. ;
Julian, Thomas B. ;
McLaughlin, Sarah A. ;
McCall, Linda ;
Symmans, W. Fraser ;
Le-Petross, Huong T. ;
Haffty, Bruce G. ;
Buchholz, Thomas A. ;
Nelson, Heidi ;
Hunt, Kelly K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14) :1455-1461
[7]   Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 [J].
Burstein, H. J. ;
Curigliano, G. ;
Loibl, S. ;
Dubsky, P. ;
Gnant, M. ;
Poortmans, P. ;
Colleoni, M. ;
Denkert, C. ;
Piccart-Gebhart, M. ;
Regan, M. ;
Senn, H. -J. ;
Winer, E. P. ;
Thurlimann, B. .
ANNALS OF ONCOLOGY, 2019, 30 (10) :1541-1557
[8]   Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Cardoso, F. ;
Kyriakides, S. ;
Ohno, S. ;
Penault-Llorca, F. ;
Poortmans, P. ;
Rubio, I. T. ;
Zackrisson, S. ;
Senkus, E. .
ANNALS OF ONCOLOGY, 2019, 30 (08) :1194-1220
[9]   Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members [J].
Caudle, Abigail S. ;
Bedrosian, Isabelle ;
Milton, Denai R. ;
DeSnyder, Sarah M. ;
Kuerer, Henry M. ;
Hunt, Kelly K. ;
Mittendorf, Elizabeth A. .
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (10) :2925-2934
[10]   Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection [J].
Caudle, Abigail S. ;
Yang, Wei T. ;
Krishnamurthy, Savitri ;
Mittendorf, Elizabeth A. ;
Black, Dalliah M. ;
Gilcrease, Michael Z. ;
Bedrosian, Isabelle ;
Hobbs, Brian P. ;
DeSnyder, Sarah M. ;
Hwang, Rosa F. ;
Adrada, Beatriz E. ;
Shaitelman, Simona F. ;
Chavez-MacGregor, Mariana ;
Smith, Benjamin D. ;
Candelaria, Rosalind P. ;
Babiera, Gildy V. ;
Dogan, Basak E. ;
Santiago, Lumarie ;
Hunt, Kelly K. ;
Kuerer, Henry M. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1072-+